When you get proper rest, your body can produce the right amount of GLP-1, helping you feel satisfied and manage blood sugar better
In 2014, Saxenda was the first GLP-1 introduced specifically for chronic weight management, followed by Wegovy in 2021 and Zepbound in 2023
The control group scored a mean of 7.5 out of 10, while the cases averaged 7.0, a statistically significant difference (P=0.046) even when adjusting for diabetes status
They also appear to decrease markers of systemic inflammation , which is critical because chronic inflammation fuels atherosclerosis (plaque buildup in arteries)
"A lot of cancer types used to be treated as a homogeneous condition," said Zehnder
[DOI] [PubMed] [Google Scholar] 71.Chen B, Yu X, Horvath-Diano C, Ortuo MJ, Tschp MH, Jastreboff AM